Valar Labs is a precision medicine company developing computational histology AI tests for predicting response to cancer therapies. Our goal is to provide every patient and physician the ability to select the best treatment based on the patient's tumor biology. Our bladder cancer test, Vesta, predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/03/24 | $22,000,000 | Series A |
Andreessen Horowitz DCVC Pear Ventures | undisclosed |
